Cervical Cancer & STIs-Cutting Edge Technologies & Management Strategies (HPV UAE)

Venue: Dubai

Location: Dubai, United Arab Emirates

Event Date/Time: Jul 01, 2009 End Date/Time: Jul 01, 2009
Registration Date: Jul 29, 2009
Early Registration Date: Jul 29, 2009
Report as Spam

Description

Cervical cancer is the second most common cancer among women worldwide , causing over 250,000 deaths annually (WHO report) . HPV (Human Papilloma Virus) is the cause of 99.7% of cervical cancer cases and HPV Genotypes 16 and 18 cause approximately 70% of cervical cancers worldwide. HPV infections are transient in most cases. Around 20% of all HPV infections persist leading to the development of cervical lesions and 1 to 10% of these lesions eventually develop into cervical cancer. Thus it is important to clearly identify those women at increased risk of developing cervical cancer at an early stage. This seminar is an effort to broaden the understanding of the combination of liquid based cytology using the Digene Hybrid capture 2 technique and the latest DNA based HPV detection technologies utilised for the prevention of cervical cancer.
Latest DNA Technologies in the Detection of Sexually Transmitted Infections:


Dr. Sanjida Ahmed, PhD (Cell Biology)
Director, Research, Eastern Biotech & Life Sciences, Dubai, UAE


Opportunistic Screening for Cervical Precancer Lesions:


Dr. Dinesh Gupta, PhD (Medical Biochemistry)
Director, National Clinical Reference Laboratory, New Delhi, India
Clinical consultant for Qiagen USA
Executive Member of Indian Association for Cancer Research (IACR)
Life Member of Asia-Oceania Research Organization on Genital Infections and Neoplasia
(AOGIN)


The Need of Clinical Education to Raise an Awareness of HPV Screening and Cervical Cancer Prevention:


Dr. Rihab Khalil Awad, MBCHB, MRCOG

Specialist Obstetrician / Gynecologist , Mitera Clinic, DHCC, Dubai
Member of the Royal College of Obstetricians & Gynecologists, UK, with special experience in Urogynecology & Laparoscopic Surgery


Vaccination - Primary Protection Against Cervical Cancer:


To be advised
Glaxo Smith Kline, Dubai, UAE


Workshop:


Poster Presentation
Demo: Sample Collection

Venue

Restrictions